natgillin/translations-raw huggingface dataset:
a fifth software module executable by the processor and the memory, the fifth software module configured to identify if the parsed field does not match the valid characteristic of the valid corresponding field; and a sixth software module executable by the processor and the memory, the sixth software module configured to determine a likelihood of modifying the parsed field that does not match the valid characteristic of the valid corresponding field to generate a valid field based upon, at least in part, one or more empirically determined rules, wherein the empirically determined rules are based upon, at least in part, possible errors that occur in the parsed field and a number of modifications to implement to correct each possible error. 
HR P20180306 T1 atributa atributa nevažećeg polja koja ne odgovaraju važećoj karakteristici važećeg polja utemeljenog na, barem djelomično, specifikacijama formata prijenosne izvršne datoteke; treći softverski modul izvršiv putem procesora i memorije, treći softverski modul konfiguriran da generira (104) model popravka za popravak nevažećeg polja prijenosne izvršne datoteke generiranjem modela popravka utemeljenog na jednom ili više empirijski izvedenih pravila, gdje jedno ili više empirijski izvedenih pravila uključuje kalkulacije radi ispravka nevažećeg polja utemeljene na, barem djelomično, prethodnim greškama i ukoliko su prethodne greške ispravljene u svrhu dobivanja izvršnih datoteka; i četvrti softverski modul izvršiv putem procesora i memorije, četvrti softverski model konfiguriran za popravak (106) nevažećeg polja prijenosne izvršne datoteke utemeljene, barem djelomično, na modelu popravka.
The aqueous pharmaceutical suspension according to claim 7, wherein the hydrocolloid gum is, by weight/volume (g/100 mL), about 0.23% to about 0.45%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidrokoloidna guma iznosi, težinski/volumno (g/100 ml), otprilike 0,23 % do otprilike 0,45 %. t>&
The filtration device of claim 1, wherein the saccharide units of said composition are selected from the group consisting of glucose, fructose, galactose, sucrose, maltose and lactose. 
Tkanina u skladu s patentnim zahtjevom 1 ili 2, pri čemu su saharidne jedinice izabrane iz skupine koja se sastoji od glukoze, fruktoze, galaktoze, saharoze, maltoze i laktoze.
A compound according to any one of claims 1 to 11 for use in the treatment of a pathological condition or disease associated with B2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities, which condition or disease is preferably selected from pulmonary diseases, pre-term labor, glaucoma, neurological disorders, cardiac disorders, inflammation and gastrointestinal disorders, and is more preferably asthma and or chronic obstructive pulmonary disease. 
Spoj prema bilo kojem zahtjevu od 1 do 11 za primjenu u liječenju patološkog stanja ili bolesti povezane s djelovanjem agonista B2 adrenergičkog receptora i antagonista muskarinskog acetilkolinskog receptora M3, pri čemu je stanje ili bolest poželjno odabrano iz plućnih bolesti, prijevremenog poroda, glaukoma, neuroloških poremećaja, srčanih poremećaja, upalnih ili gastrointestinalnih poremećaja, a poželjnije je astma ili kronična opstruktivna plućna bolest.
A process for the preparation of an aqueous slurry having a solids content of more than 78 wt%, characterized in that a first fraction F1 of a mineral material is provided which has a percentage P5(F1) by weight of particles having a diameter of less than 5.0 µm of from 75 % to 85 % and a median particle diameter d50 of from 2.0 to 3.0 µm, and a second fraction F2 of a mineral material is provided which has a percentage P2(F2) by weight of particles having a diameter of less than 2.0 µm of from 85 % to 100 % and a median particle diameter d50 of from 0.3 to 0.65 µm, and both fractions are dispersed in water. 
Postupak priprave vodenog mulja koji ima sadržaj čvrstih tvari veći od 78 %, težinski, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se dodaje prvu frakciju F1 mineralnog materijala, koja ima postotak Ps(F1), težinski, čestica promjera manjeg od 5,0 um od 75% do 85%, uz srednji promjer čestica dsg od 2,0 do 3,0 um, te se dodaje drugu frakciju F2 mineralnog materijala, koja ima postotak P2(F2), težinski, čestica promjera manjeg od 2,0 um od 85 % do 100 %, uz srednji promjer čestica dsg od 0,3 do 0,65 um, gdje su obje frakcije dispergirane u vodi.
The compound of any one of claims 1-4, wherein Z is -NR5- or 
Tvar iz bilo kojeg od patentnih zahtjeva 1-4, gdje je Z i) ii)
The names stated in brackets are the trade names by which the materials are known commercially. 
Oznake navedene u zagradama su trgovačka imena, pod kojima se dotični materijali nalaze na tržištu.
The method of claim 4, wherein the CDK4/6 inhibitor is administered to the human about 4 hours or less prior to administration of carboplatin and etoposide on day 1 of the 21-day chemotherapeutic treatment cycle. 
Spoj ili sol za upotrebu prema bilo kojem od zahtjeva 1 do 11, gdje se razgradnja spoja ili soli CDK4/6 inhibitornog efekta događa u manje od 36 sati od davanja spoja.
(73 after 2 days) 
(73) Nositelj patenta:
Compound of any one of claims 1 to 7 for use in the treatment, prevention or amelioration of disorders in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor wherein the disorder is preferably selected from the group consisting of pain, diarrhea, or emesis. 
Spoj prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu kod liječenja, sprečavanja ili ublažavanja poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora.
A combination according to claim 1 wherein the antagonist of M3 muscarinic receptor (b) is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide. 
Kombinacija sukladno patentnom zahtjevu 1, naznačena time, da je antagonist M3 muskarinskih receptora (b) (3R)-1-fenetil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo [2.2.2|oktan bromid.
A polymer washout solvent according to one of the preceding claims 1-4, wherein the ether hydrocarbon component comprises a di-ether of an C1-C8 alkane derived from a diol, and two C1-C3 alkoxy groups. 
Otapalo za ispiranje polimera prema jednom od prethodnih zahtjeva 1-3, naznačeno time da eter komponenta ugljikovodika sadrži di-eter C1-C8 alkana dobivenog od diola, te dvije C1-C3 alkoksi skupine.
represents hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy; 
predstavlja vodik ili C1-4alkil po izboru supstituiran s C1-4alkoksi;
A preparation comprising the pharmaceutical composition as defined in any one of claims 4 to 7 in combination with a drug selected from the group consisting of corticosteroids, anthralin, coal tar, calcitriol, tazarotene, salicylic acid, methotrexate (MTX), cyclosporin, retinoids, alefacept, efalizumab, etanercept and adalimumab. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je namijenjen kombiniranoj upotrebi s drugim farmaceutskim pripravkom koji sadrži spoj kojeg se bira iz skupine koju čine kortikosteroidi, antralin, ugljeni katran, kalcitriol, tazaroten, salicilna kiselina, metotreksat (MTX), ciklosporin, retinoidi, alefacept, efalizumab, etanercept i adalimumab.
treating said compound of formula IIIb with a compound of formula II to form a compound of formula I; 
(1i) obrade navedenog spoja formule IIIb spojem formule II kako bi se dobio spoj formule I:
A method of providing a peakless long acting basal insulin in the treatment of Type I or Type II Diabetes Mellitus in a patient in need thereof comprising subcutaneously administering to the patient an aqueous pharmaceutical formulation comprising 300 U/mL insulin glargine [equimolar to 300 IU human insulin]. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
The method of any of paragraphs 40 to 44, wherein said fusion protein includes a polypeptide portion selected from the group consisting of: an immunoglobulin Fc domain and a serum albumin. 
Polipeptid za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je polipeptid fuzijski protein uključujući, kao dodatak varijanti ActRIIB domene polipeptida, dio polipeptida odabran od skupine koja se sastoji od: domene imunoglobulina Fc 1 albumin seruma.
The optically variable pigments and coating compositions which are sold for decorative applications are not suited for magnetic orientation; 
Optički varijabilni pigmenti i smjese za premazivanje koje se prodaju za dekorativne namjene nisu prikladni za korištenje postupka magnetskog usmjeravanja; ii)
Table 1: Binding and CTF Assays 
Tablica 1 Ispitivanja vezanja i CTF-a
Surfactants that may be used in compositions or formulations of the invention include polyoxyethylene castor oil compounds, polyoxyethylene mono- and di-fatty acid esters, mixtures of polyoxyethylene mono- and di-esters of C8-C22 fatty acids and glyceryl mono-, di- and tri-esters of C9-C22 fatty acids (e.g., sold under trade names Gelucire 44/14, Gelucire 50/13, Gelucire 53/10 by Gattefosse), d-a-tocopheryl polyethylene glycol 1000 succinate, polyoxyethylene-polyoxypropylene copolymers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, sodium dioctyl sulfosuccinate, sodium lauryl sulfate, sorbitan fatty acid esters, sugar fatty acid esters, or a mixture of any two or more thereof. 
Sastav prema patentnom zahtjevu 3, naznačen time, da se površinski aktivna tvar odabire od spojeva polioksietilena i ricinusovog ulja, polioksietilen monoestera i diestera masnih kiselina, smjesa polioksietilen monoestera i diestera Cg-C,, masnih kiselina i gliceril monoestera, diestera i triestera Cg-C,, masnih kiselina, &- tokoferil polietilen glikol 1000 sukcinata, polioksietilen-polioksipropilen kopolimera, polioksietilen sorbitan estera masnih kiselina, polioksietilen alkil etera, natrij dioktil sulfosukcinata, natrij lauril sulfata, sorbitan estera masnih kiselina, šećernih estera masnih kiselina ili smjesa od bilo kojih od dvoje ili od više njih.
The mixture was stirred for 4 hours at 40° C., then the solvent was evaporated off. 
Smjesa je miješana 4 sati pri 40%, te je otapalo upareno.
Use according to any of claims 10-12, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week or until biomarkers of liver function are within normal limits. Use according to any of claims 10-13, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits, and optionally about 1600 mg/day or 1602 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits. 
Upotreba prema zahtjevu 10-13 gdje je, prije stupnja (a), davanje pirfenidona pacijentu prekinuto u tijeku vremenskog perioda, opcijski jedan tjedan ili do vraćanja biomarkera funkcije jetre u opseg normalne vrijednosti, Upotreba prema bilo kojem od zahtjeva 10-14, gdje je prije stupnja (a), 800 mg/dan ili 801 mg/dan pirfenidona davano pacijentu u tijeku vremenskog perioda, opcijski jednom tjedno ili do vraćanja biomarkera funkcije jetre u opseg normalnih vrijednosti i opcijski davano je 1600 mg/dan ili 1602 mg/dan pirfenidona pacijentu u tijeku vremenskog perioda, opcijski jedan tjedan, ili do vraćanja biomarkera funkcije jetre u opseg normalnih vrijednosti.
(q-1) reacting Compound (K) with trimethylsilyl acetylene to form Compound (L) 
(q-1)reakciji Spoja (K) s trimetilsililacetilenom kako bi se dobilo Spoj (L)
An intermediate of Formula (II): wherein: 
Intermedijer formule (II): [image] naznačen time, što:
A TGFB antagonist for use in a method for inhibiting breast cancer associated tumor growth in a subject, the method comprising administering to said subject a therapeutically effective amount of the TGFB antagonist in combination with capecitabine and ixabepilone, wherein the administration of said TGFB antagonist enhances the efficacy of capecitabine and ixabepilone to inhibit said breast cancer associated tumor growth. 
Farmaceutski pripravak za liječenje raka dojke kod subjekta, koji sadrži: terapijski učinkovitu količinu antagonista transformirajućeg faktora rasta beta (TGFß), kapecitabina, te iksabepilon, naznačen time da je navedeni antagonist TGFß prisutan u količini koja učinkovito pojačava učinkovitost kapecitabina i iksabepilona u liječenju navedenog raka dojke.
a recess for hand insertion; an electrochemical cell provided with a timer, configured to produce an oxidant solution by electrolysis of an aqueous electrolytic medium during a predefined time; 
- < elektrokemijskom ćelijom (4) opremljenom mjeračem vremena, prikladnomu za proizvodnju oksidacijske otopine elektrolizom vodenog medija tijekom prethodno određenog vremena;
wherein R1 and R2 are each independently hydrogen or organic group; XA and XB are each independently a bond, alkylene, alkenylene, -CO-, -SO2-, or -CONH-, wherein each of the alkylene and alkenylene chains can optionally contain one or more substituents selected from the group consisting of -S-, -C(=S)-, -SO2-, -CO-, -O-, -NH-, -CONH- and -SO2NH-, and the hydrogen atom (H) bonded to the nitrogen atom (N) in XA and XB is optionally substituted with a substituent selected from the group consisting of lower alkyl, phenyl lower alkyl and phenyl; 
XA i XB su svaki neovisno veza, alkilen, alkenilen, -CO-, -SO2-, ili -CONH-, gdje svaki od alkilen-lanaca ili alkenilen-lanaca, može po želji sadržavati jedan ili više supstituenata odabranih iz skupine koju čine: -S-, -C(=S)-, -SO2-, -CO-, -O-, -NH-, -CONH- i -SO2NH-, te kada je vodikov atom (H) spojen na dušikov atom (N) u XA i XB se po želji supstituira sa supstituentom odabranim iz skupine koju čine C1-6-alkil, fenil C1-6-alkil i fenil.
For column equilibration, the column was flushed with 6 or more BV of equilibration buffer, PBS 1X pH 6.1±0.1, 1 NaCl, conductivity 95±5 mS/cm. pH and conductivity were checked, and washing continued if the parameters of the column's effluent are out of target values, i.e. pH 6.1±0.1, 1 NaCl, conductivity 95±5 mS/cm. 
Za uravnoteživanje kolone, ista je bila oprana s 6 ili više BV pufera za uravnoteženje, PBS IX pH 6.1 £0.1, 1 NaCl, i provodljivosti od 95 + 5 mS/em. pH i provodljivost su bili provjereni, a s ispiranjem je nastavljeno ukoliko su vrijednosti protoka kroz kolonu bili izvan ciljnih vrijednosti primjerice pH 6.1 + 0.1,1 NaCl, i provodljivosti od 95 + 5 mS/cm.
with an orthoester (XX) where R may be H or methyl, and wherein the compound of the formula (XVIII) is prepared by reacting compounds of the formula (XVI a,b) 
Postupak za pripravu spoja s formulom (XVIII) naznačen time što spojevi s formulom (XVI a,b) reagiraju sa spojem s formulom (IX)
The composition according to any one claims 17 or 18, characterized in that it further comprises additives such as dispersing agents, siliconizing agents, thickeners, rheology modifiers, anti-settling agents, defoamers, antioxidants, bluing agents, surfactants, crosslinkers, flame retardants, catalysts, pH buffers, fillers, dyes, pigments, optical brightners, waxes, coalescence agents, biocides and mixtures thereof. 
Pripravak prema bilo kojem od zahtjeva 17 ili 18, naznačen time da dodatno sadrži aditive kao što su disperzijska sredstva, sredstva za silikoniziranje, sredstva za zgušnjavanje, modifikatori reoloških svojstava, sredstva protiv taloženja, sredstva protiv pjenjenja, antioksidansi, sredstva za bijeljenje rublja, surfaktanti, sredstva za umrežavanje, usporivači plamena, katalizatori, pH puferi, punila, bojila, pigmenti, optički posvjetljivači, voskovi, sredstva za srastanje, biocidi i njihove smjese.
R is selected from linear or branched C1-C16, preferably C1-C8, alkyl groups, C3-C16, preferably C3-C8, cycloalkyl groups, optionally substituted, allyl groups, phenyl optionally substituted; 
- R se bira između nerazgranatih ili razgranatih C,-C;g alkilnih skupina, izborno supstituiranih C3-C14 cikloalkilnih skupina, alilnih skupina, izborno supstituiranog fenila;
A radio communication method implemented in a radio communication terminal apparatus, the method comprising: 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je:
wherein is hydrogen, alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, halogen, cyano, aryl, OR2, S(O)nR3, NR4R5 or a heterocyclic group which may be substituted by alkyl; 
(a naznačen time, da je R! alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, halogen, cijano, aril, heterociklička skupina, OR", S(O),R*, NR*R';
an antibody of any one of items 1 to 20, or a pharmaceutical composition thereof; 
(a) protutijelo prema bilo kojem od zahtjeva 1 do 7, ili njegov farmaceutski sastav;
refining this suspension. 
rafiniranje ove suspenzije.
A compound for use according to any one of claims 1 to 11 wherein the disorder is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
Spoj namijenjen upotrebi u skladu s patentni zahtjevom 18, naznačen time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska fibroza pluća (IPF), virusne infekcije dišnog sustava, virusna egzacerbacija respiratornih bolesti, aspergiloza, lišmenijaza, alergijski rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bubrežna bolest, agregacija trombocita, rak, pokretljivost sjemena, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, post hepatski neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
The amino acid sequence of the SGIV light chain is provided in SEQ ID NO:90. 
(1) područje slabog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO:90;
The liquid, unit-dose pharmaceutical composition of claim 11, wherein said azelastine is present in said composition at a concentration of about 0.1% by weight and said sucralose is present in said composition at a concentration of about 0.15% by weight. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni azelastin prisutan u navedenom pripravku u koncentraciji od 0,1%, težinski, a navedena sukraloza je prisutna u navedenom pripravku u koncentraciji od 0,15%, težinski.
wherein the endothelial chamber is composed of a space formed between the endothelial lid and the intermediate component after a tight connection of the endothelial lid to the intermediate component; 
komora za endotel (18) se sastoji od prostora načinjenog između poklopca za endotel (4) i međukomponente (2), nakon čvrstog povezivanja navedenog poklopca za endotel s navedenom komponentom;
wherein the lower covering part comprises an edge that laterally covers a portion of the base body, wherein the edge of the lower covering part is separated into two opposing areas; and 
b) donji pokrovni dio (100) obuhvaća rub (102) koji lateralno pokriva bazno tijelo (41), rub donjeg pokrovnog elementa odvojen je u dva suprotna područja (103, 104);
Microaggregates of IL-2 and SDS begin to form at about 500-600µg/mg, and their size gradually increases as the SDS level is further decreased to the target 160µg/mg level (Figure 1). 
Mikroagregati IL-2 i SDS se počinju oblikovati pri oko 500-600ug/mg, a njihova se veličina postepeno povećava kako se razina SDS dalje smanjuje do ciljane razine od 160ug/mg (Slika 1).
A pharmaceutical aerosol solution composition according to claim 1 wherein the overall formoterol degradation products level is lower than 10% w/w with respect to the theoretical formoterol fumarate content of 6µg/actuation and the residual level of formoterol fumarate is higher than 90% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 u kojem je ukupna razina degradacijskog produkta formoterola niža od 10% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 90% w/w prema njegovom početnom sadržaju.
Compound of formula (I) according to any one of claims 1 to 19, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 34 ili adicijske soli istog s farmaceutski prihvatljivom kiselinom ili lužinom, naznačena time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
Stirred at room temperature for 4h, then the solvent was removed by evaporation and the residue was dissolved in ethyl acetate and water. 
Miješa se na sobnoj temperaturi kroz 4 sata, potom se otapalo ukloni uparavanjem i ostatak se otopi u etil acetatu i vodi.
The peptide according to any of Claims 1 to 3, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta.
Fluid-bed granulation process comprising the steps: an aqueous solution of pimobendan and a binder is sprayed onto a solid support comprising one or several carriers and/or excipients, flavor and citric acid anhydrous; and 
Postupak granulacije na fluidiziranom sloju, naznačen time, da obuhvaća sljedeće korake: a) vodena otopina pimobendana i veziva se raspršuje na kruti nosač koji sadrži jedan ili nekoliko nosača, jedno ili nekoliko pomoćnih sredstava, dodatak za okus i anhidrid limunske kiseline; 1 b) smjesa iz koraka a) se suši; i
providing a basal cell culture media; supplementing the basal cell culture media with copper to provide a final copper concentration between 2.4 µg/L and 20 µg/L copper; 
(b) kompletiranja osnovnog medija za uzgoj stanica bakrom kako bi se osiguralo konačnu koncentraciju bakra između 2,4 ug/l i 20 ug/l bakra;